Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 4/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | HTR1E | P28566 | 1/20 | 0.34 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1044376 | 1.00 | HPGD (0.40) | HPGDGAASLC6A3TDP1ALDH1A1 | |
| SCHEMBL3743645 | 1.00 | HPGD (0.40) | HPGDGAASLC6A3TDP1ALDH1A1 | |
| SCHEMBL3103010 | 1.00 | HPGD (0.40) | HPGDGAASLC6A3TDP1ALDH1A1 | |
| SCHEMBL970614 | 0.88 | CYP26A1 (0.37) | HPGDGAASLC6A3ALDH1A1 | |
| SCHEMBL464738 | 0.84 | ACACB (0.44) | LMNAL3MBTL1MAPT | |
| SCHEMBL4891377 | 0.82 | SLC6A3 (0.32) | SLC6A3 | |
| SCHEMBL2443114 | 0.82 | TDP1 (0.36) | HPGDGAASLC6A3TDP1ALDH1A1 | |
| SCHEMBL2176858 | 0.73 | — | — | |
| SCHEMBL6246290 | 0.72 | SLC6A3 (0.38) | SLC6A3ATML3MBTL1SMN1; SMN2NPSR1 | |
| SCHEMBL4684382 | 0.72 | HPGD (0.43) | HPGDGAASLC6A3ALDH1A1RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8350048-B2 | Amide compounds as boosters of antivirals | JANSSEN R&D IRELAND (IE) | 2013-01-08 | — | — | US | disclosed |
| US-8163766-B2 | Beta-secretase modulators and methods of use | AMGEN INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-20120053200-A1 | BACE 2 INHIBITORS | HOFFMANN-LA ROCHE INC. | 2012-03-01 | — | — | US | disclosed |
| US-20110257111-A1 | Hydroxyethlamino Sulfonamide Derivatives | CONCERT PHARMACEUTICALS, INC. | 2011-10-20 | — | — | US | disclosed |
| US-7973047-B2 | Beta-Secretase modulators and methods of use | AMGEN INC. (US) | 2011-07-05 | — | — | US | disclosed |
| US-20110118250-A1 | BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2011-05-19 | — | — | US | disclosed |
| US-7872009-B2 | Beta-Secretase modulators and methods of use | AMGEN INC. (US) | 2011-01-18 | — | — | US | disclosed |
| US-20100305073-A1 | AMIDE COMPOUNDS AS BOOSTERS OF ANTIVIRALS | TIBOTEC BVBA | 2010-12-02 | — | — | US | disclosed |
| US-20100222338-A1 | BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. | 2010-09-02 | — | — | US | disclosed |
| US-20070185103-A1 | Beta-secretase modulators and methods of use | AMGEN INC. | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222338-A1 | BETA-SECRETASE MODULATORS AND METHODS OF USE | BACE1, BACE2, APP | HPGD 2315/4885GAA 37/4885SLC6A3 4713/4885 |
| US-20110118250-A1 | BETA-SECRETASE MODULATORS AND METHODS OF USE | BACE1, BACE2, APP | HPGD 2249/4885GAA 44/4885SLC6A3 4717/4885 |
| US-20070185103-A1 | Beta-secretase modulators and methods of use | BACE1, BACE2, APP | HPGD 2249/4885GAA 44/4885SLC6A3 4717/4885 |
| US-20120053200-A1 | BACE 2 INHIBITORS | BACE2, BACE1, PSEN2 | HPGD 1636/4885GAA 25/4885SLC6A3 1641/4885 |
| US-20100305073-A1 | AMIDE COMPOUNDS AS BOOSTERS OF ANTIVIRALS | CYP3A5, CYP3A4, CYP3A43 | HPGD 493/4885GAA 87/4885SLC6A3 1795/4885 |
| US-20110257111-A1 | Hydroxyethlamino Sulfonamide Derivatives | HTRA1, PRSS8, PRSS1 | HPGD 477/4885GAA 54/4885SLC6A3 720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.